APA (7th ed.) Citation

Coutzac, C., Bigot, F., Vansteene, D., Dos Santos, M., Ghiringhelli, F., You, B., . . . Le Tourneau, C. (2023). 557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology, 34, S415. https://doi.org/10.1016/j.annonc.2023.09.1748

Chicago Style (17th ed.) Citation

Coutzac, C., et al. "557MO Phase II Trial Evaluating the Efficacy of Pembrolizumab Combined with Vorinostat in Patients with Recurrent And/or Metastatic Anal Squamous Cell Carcinoma: Subgroup Analysis of the PEVOsq Basket Trial." Annals of Oncology 34 (2023): S415. https://doi.org/10.1016/j.annonc.2023.09.1748.

MLA (9th ed.) Citation

Coutzac, C., et al. "557MO Phase II Trial Evaluating the Efficacy of Pembrolizumab Combined with Vorinostat in Patients with Recurrent And/or Metastatic Anal Squamous Cell Carcinoma: Subgroup Analysis of the PEVOsq Basket Trial." Annals of Oncology, vol. 34, 2023, p. S415, https://doi.org/10.1016/j.annonc.2023.09.1748.